Lomalizumab: un nouvel anti-IgE pour le traitement de lasthme sévère | Zendy

AI Assistant Blog Pricing

Open Access

Lomalizumab: un nouvel anti-IgE pour le traitement de lasthme sévère

Author(s) -

Philip Taramarcaz,

Carl J. Hauser

Publication year - 2008

Publication title -

forum médical suisse ‒ swiss medical forum

Language(s) - French

Resource type - Journals

eISSN - 1661-6146

pISSN - 1661-6138

DOI - 10.4414/fms.2008.06432

Subject(s) - omalizumab , medicine , immunoglobulin e , antibody , immunology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Download on the

Discover

Explore

Copyright Knowledge E © 2026. All Rights Reserved.